Psyence Biomedical (PBM)

• Market cap: $3.21M
• 1 day: -6.30%
• 5 days: -37.45%
• 1 month: -52.71%
• 3 months: -90.43%
• 6 months: -94.06%
• Year to date: -97.85%
• 1 year: -97.85%
• 5 years: -97.85%
• 10 years: -97.85%

About: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Employees: 10

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

20% more funds holding

Funds holding: 10 [Q2] → 12 (+2) [Q3]

1.52% more ownership

Funds ownership: 10.54% [Q2] → 12.06% (+1.52%) [Q3]

30% less capital invested

Capital invested by funds: $286K [Q2] → $201K (-$85K) [Q3]